✓ verified = confirmed by human source
◇ research = AI-assisted, pending confirmation
Status◇ research
Acquired
Status Detail
Acquired (operating as Photonamic subsidiary)
Exit Type◇ research
Acquisition
Subsequent Funding◇ research
$0
Received VC Funding◇ research
Yes
Current Employees◇ research
11
Peak Employees◇ research
—
Relocated◇ research
Yes — Kentucky
SBIR/STTR Awards◇ research
—
Filed Form D◇ research
Yes
Used Crowdfunding◇ research
—
Notes
SEC Form D shows Louisville address in 2016; current site and LinkedIn show Lexington operations. NX Development says it became a Photonamic subsidiary in 2018 and remains active around Gleolan.
[Deep research 2026-04-11] Acquired by Photonamic GmbH & Co. KG in 2018. Gleolan received FDA approval in 2017. Currently headquartered in Lexington, KY at 870 Corporate Drive. Active clinical trials include Phase 3 OVA-302 ovarian cancer study (first patient enrolled June 2024) and Phase 3 MEN-301 meningioma study. Received FDA Orphan Drug Designation for ovarian cancer indication.
Last updated: Apr 11, 2026 · Evidence score: 5/5